AGR2 has been reported to be a prognostic marker in several hormonally-regulated cancers such as those of breast [11, 12], prostate [13] and ovary [14], where it is involved in drug resistance [15, 16] and metastatic growth [17]. Here, AGR2 is linked to cancer.